A Phase III international, randomised, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 150 mg of oral oseltamivir twice daily in the treatment of hospitalised adults and adolescents with influenza

Trial Profile

A Phase III international, randomised, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 150 mg of oral oseltamivir twice daily in the treatment of hospitalised adults and adolescents with influenza

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Oseltamivir (Primary) ; Zanamivir (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 19 Feb 2015 Status changed from recruiting to active, no longer recruiting as per UKCRN record.
    • 25 Feb 2012 Additinoal trial location (Wales) identified as reported by UKCRN.
    • 19 Jan 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top